Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Turn Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Research and development
0.25
0.27
General and administrative
1.55
5.59
Operating expenses
1.8
5.86
Operating income
-1.8
-5.86
Interest income
0.03
0.03
Other non-operating income
0.03
2.66
Net income
-1.77
-3.19
EBITDA
-1.75
-5.81
EPS, basic
-0.07
-0.12
EPS, diluted
-0.07
-0.12
Shares, basic (weighted)
26.6
27.7
Shares, diluted (weighted)
26.6
27.7
Balance sheet
FY2025
FY2025
Cash and equivalents
0.5
4.03
Other current assets
0.23
0.12
Total current assets
1.1
5.2
Lease right-of-use assets
0.12
0.08
Intangible assets
0.82
0.92
Total assets
2.05
12.2
Total current liabilities
0.71
6
Lease liabilities
0.08
0.03
Total liabilities
2.23
7.48
Paid-in capital
19
28.1
Retained earnings
-19.2
-22.4
Shareholders' equity
-0.18
4.69
Total equity
-0.18
4.69
Total liabilities and equity
2.05
12.2
Shares outstanding
26.8
29.4
Cash flow statement
FY2025
FY2025
Net income
-1.77
-3.19
Depreciation and amortization
0.05
0.05
Stock-based compensation
0.35
0.42
Change in payables
0.2
2.26
Cash from operations
-1.36
-2.56
Cash from investing
-0.1
-0.15
Stock issued
1.15
6.92
Cash from financing
1.15
6.92
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $9.92 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-224.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-78.1%
Net income / average total assets.
Return on invested capital (ROIC)
-158.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
493.6%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
4.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.19x
Current assets / current liabilities.
Quick ratio
2.71x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.71x
(Cash + short-term investments) / current liabilities.
Debt / equity
1.28x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
44.4%
Total debt / total assets.
Liabilities / assets
65.2%
Total liabilities / total assets.
Net debt
-$2.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.18
Cash from operations / diluted weighted shares.
Book value per share
$0.19
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
51.9x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
61.8x
Market cap / tangible book value, when positive.
Earnings yield
-4.3%
Net income / market cap (the inverse of P/E).
Was Turn Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $3.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.